Literature DB >> 19487793

The influence of commonly used immunosuppressive drugs on the small bowel functions - a comparative experimental study.

Maciej Malinowski1, Peter Martus, Peter Neuhaus, Martin Stockmann.   

Abstract

BACKGROUND: Gastrointestinal side effects of immunosuppressive drugs have got a high importance in clinical practice. The aim of this basic experimental study was to characterize the direct and immediate influence of seven commonly used immunosuppressive drugs on the small bowel functions. Therefore, the influence of ciclosporin A, tacrolimus, mycophenolate mofetil, enteric coated MPA, sirolimus, everolimus and FTY720 on-glucose absorption (I-GLU), chloride secretion (I-CHL), and barrier function (I-BAR) was investigated.<br /> MATERIAL/
METHODS: Jejunum of Wistar rats was mounted into modified Ussing-chambers and thereafter incubated with a low (therapeutic) or high (toxic) concentration of immunosuppressive drugs for one hour. I-GLU was measured by 3-O-methyl-D-glucopyranose kinetics. I-CHL was assessed through basal, bumetanide inhibited and theophylline + PgE(2 )activated short circuit current difference. I-BAR was assessed by transepithelial resistance and( 3)H-Lactulose-Flux.<br />
RESULTS: No differences were observed within the analyzed parameters whether immunosuppressive drugs were added from mucosal or serosal intestine side. The glucose absorption was not influenced by any of the analyzed immunosuppressive drugs. The small intestine barrier function was diminished by everolimus in the toxic group only. Only mycophenolate mofetil and EC-MPA decreased chloride secretion in the toxic concentration. None of the analyzed drugs increased chloride secretion.<br />
CONCLUSIONS: In conclusion, the analyzed immunosuppressive drugs had no direct and immediate influence on gastrointestinal function in therapeutic concentrations. However, toxic concentrations of mycophenolate mofetil, enteric coated MPA, and everolimus might be of importance for local effects on small bowel function due to oral application.<br /> <br /> <br />

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19487793

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  3 in total

1.  Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment.

Authors:  Candice E Van Skike; Jordan B Jahrling; Angela B Olson; Naomi L Sayre; Stacy A Hussong; Zoltan Ungvari; James D Lechleiter; Veronica Galvan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-12-22       Impact factor: 4.733

2.  End-Stage Renal Disease-Associated Gut Bacterial Translocation: Evolution and Impact on Chronic Inflammation and Acute Rejection After Renal Transplantation.

Authors:  Clémence Carron; Jean-Paul Pais de Barros; Emilie Gaiffe; Valérie Deckert; Hanane Adda-Rezig; Caroline Roubiou; Caroline Laheurte; David Masson; Dominique Simula-Faivre; Pascale Louvat; Bruno Moulin; Luc Frimat; Philippe Rieu; Christiane Mousson; Antoine Durrbach; Anne-Elisabeth Heng; Philippe Saas; Didier Ducloux; Laurent Lagrost; Jamal Bamoulid
Journal:  Front Immunol       Date:  2019-08-16       Impact factor: 7.561

3.  Tacrolimus Induces Insulin Resistance and Increases the Glucose Absorption in the Jejunum: A Potential Mechanism of the Diabetogenic Effects.

Authors:  Zhiwei Li; Fei Sun; Yaohui Zhang; Hao Chen; Ningning He; Hui Chen; Penghong Song; Yan Wang; Sheng Yan; Shusen Zheng
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.